OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth
OmniAb NASDAQ: OABI used its investor and analyst day to outline its strategy for expanding royalty-bearing partnerships, commercializing its xPloration screening platform and entering the peptide-discovery market through its newly introduced OmniTides platform.
OmniAb, Inc. (OABI) Analyst/Investor Day Transcript
OmniAb, Inc. (OABI) Analyst/Investor Day Transcript
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy
OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech
OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships like the recent Eli Lilly deal. OABI's 110 partners and 425 programs are generating higher, more predictable milestone revenues, with $340M in clinical-stage milestone potential and a $3B+ total milestone pool. The Lilly collaboration validates OABI's technology, offers high-margin, capital-light economics, and has directly improved 2026 cash guidance to $49–$53M.
OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript
OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript
OmniAb Q2 Earnings Call Highlights
OmniAb NASDAQ: OABI reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and year-end cash outlook.
OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.15 per share a year ago.
OmniAb Q1 Earnings Call Highlights
OmniAb NASDAQ: OABI reported first-quarter 2026 results that management characterized as a “very strong start to the year,” driven primarily by clinical progress across its partner portfolio and associated milestone revenue. Get OmniAb alerts:Sign UpPartner program progress drives revenue outperformance President and CEO Matt Foehr said the company continues to see partner programs derived from OmniAb's technologies move into the clinic and into later-stage development, which he described as the point where the licensing model translates into “clearer and more visible value” through potential future milestones and royalties.
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago.
OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript
OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript
OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.12 per share a year ago.
OmniAb, Inc. (OABI) Discusses Launch and Scientific Overview of OmniUltra Technology Platform Transcript
OmniAb, Inc. (OABI) Discusses Launch and Scientific Overview of OmniUltra Technology Platform Transcript
